Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities

The aim of a phase I oncology trial is to identify a dose with an acceptable safety profile. Most phase I designs use the dose-limiting toxicity, a binary endpoint, to assess the unacceptable level of toxicity. The dose-limiting toxicity might be incomplete for investigating molecularly targeted the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ezzalfani, Monia, Zohar, Sarah, Qin, Rui, Mandrekar, Sumithra J, Deley, Marie-Cécile Le
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons 2013
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813987/
https://www.ncbi.nlm.nih.gov/pubmed/23335156
http://dx.doi.org/10.1002/sim.5737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813987/
https://www.ncbi.nlm.nih.gov/pubmed/23335156
http://dx.doi.org/10.1002/sim.5737

Ejemplares similares